[HTML][HTML] Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice

T Hosoi, S Yokoyama, S Matsuo, S Akira, K Ozawa - PloS one, 2010 - journals.plos.org
T Hosoi, S Yokoyama, S Matsuo, S Akira, K Ozawa
PloS one, 2010journals.plos.org
Background Multiple lines of evidence suggest innate immune response pathways to be
involved in the development of obesity-associated diabetes although the molecular
mechanism underling the disease is unknown. Recent observations suggest that saturated
fatty acids can act as a ligand for toll-like receptor (TLR) 4, which is thought to mediate
obesity-associated insulin resistance. Myeloid differentiation factor 88 (MyD88) is an adapter
protein for TLR/IL-1 receptor signaling, which is involved in the activation of inflammatory …
Background
Multiple lines of evidence suggest innate immune response pathways to be involved in the development of obesity-associated diabetes although the molecular mechanism underling the disease is unknown. Recent observations suggest that saturated fatty acids can act as a ligand for toll-like receptor (TLR) 4, which is thought to mediate obesity-associated insulin resistance. Myeloid differentiation factor 88 (MyD88) is an adapter protein for TLR/IL-1 receptor signaling, which is involved in the activation of inflammatory pathways. To evaluate molecular mechanisms linking obesity-associated diabetes down-stream of TLR4, we investigated physiological role of MyD88 in high-fat diet (HFD)-induced obesity.
Methodology/Principal Findings
In the present study, we found MyD88-deficient mice fed a HFD had increased circulating levels of insulin, leptin and cholesterol, as well as liver dysfunction (increased induction of ALT levels, increased activation of JNK and cleavage of PARP), which were linked to the onset of severe diabetes. On the other hand, TNF-α would not be involved in HFD-induced diabetes in MyD88-deficient mice, because TNF-α level was attenuated in MyD88-deficient mice fed with HFD.
Conclusions/Significance
The present finding of an unexpected role for MyD88 in preventing diabetes may provide a potential novel target/strategy for treating metabolic syndrome.
PLOS